Centiva Capital LP Has $371,000 Stock Position in Ingevity Co. (NYSE:NGVT)

Centiva Capital LP reduced its position in shares of Ingevity Co. (NYSE:NGVT) by 21.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,513 shares of the company’s stock after selling 2,583 shares during the period. Centiva Capital LP’s holdings in Ingevity were worth $371,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in NGVT. Wealth Enhancement Advisory Services LLC raised its position in Ingevity by 3.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 7,449 shares of the company’s stock valued at $326,000 after purchasing an additional 279 shares in the last quarter. Wedge Capital Management L L P NC lifted its stake in shares of Ingevity by 4.4% in the 2nd quarter. Wedge Capital Management L L P NC now owns 143,493 shares of the company’s stock valued at $6,272,000 after acquiring an additional 6,009 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Ingevity by 101.8% in the 2nd quarter. Blue Trust Inc. now owns 896 shares of the company’s stock valued at $43,000 after acquiring an additional 452 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in shares of Ingevity by 809.2% in the 2nd quarter. First Horizon Advisors Inc. now owns 591 shares of the company’s stock valued at $26,000 after acquiring an additional 526 shares during the last quarter. Finally, Louisiana State Employees Retirement System lifted its stake in shares of Ingevity by 1.8% in the 2nd quarter. Louisiana State Employees Retirement System now owns 17,000 shares of the company’s stock valued at $743,000 after acquiring an additional 300 shares during the last quarter. 91.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, BMO Capital Markets increased their price target on Ingevity from $40.00 to $47.00 and gave the company a “market perform” rating in a research note on Thursday, October 31st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.17.

Ingevity Stock Down 1.1 %

Shares of NYSE:NGVT opened at $46.59 on Tuesday. The firm has a market cap of $1.69 billion, a P/E ratio of -3.00 and a beta of 1.62. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 6.52. Ingevity Co. has a 12-month low of $30.90 and a 12-month high of $56.29. The business has a fifty day simple moving average of $41.39 and a 200 day simple moving average of $41.54.

Ingevity (NYSE:NGVT) last announced its earnings results on Tuesday, October 29th. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.50. The business had revenue of $376.90 million during the quarter, compared to analyst estimates of $376.95 million. Ingevity had a positive return on equity of 24.46% and a negative net margin of 38.11%. Ingevity’s revenue for the quarter was down 15.5% compared to the same quarter last year. During the same period last year, the company earned $1.21 EPS. Analysts predict that Ingevity Co. will post 2.55 earnings per share for the current year.

About Ingevity

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.